2004Chongqing Yike Daxue xuebaoRequires access

A study on the pathological efficacy of lamivudine in the treatment of chronic hepatitis B

Yang Chun

Open publisher page 0 citations

Abstract

Objective:To investigate hepatic pathohistological changes(including pathology,HBV markers in liver tissue) in patients with chronic hepatitis B treated with lamivudine.Methods:35 patients of chronic hepatitis B were randomly selected and administered with 100mg lamivudine orally daily for 1 year.The needle biopsy of liver were performed before and after treatment.The routine HE stained liver tissue sections were evaluated and Knodell pathological score were done.HBsAg,HBcAg,α-SMA in liver tissue were examined by immunohistochemisty method.Results:After 1 year histological assessment revealed that activity index of hepatic histology in 41.18% patients had a significant decrease,while necrosis in portal area,portal vein phlebitis and fibrosis were oboviously alleviated.The liver immunohistochemistry examination showed that HBcAg and α-SMA in liver decreased significantly in the patients with HBeAg seroconversion,but HBsAg had no obvious alteration.Conclusion:These results suggest that lamivudine(100mg/d) alleviate the inflammation degree,slow down the development of liver fibrosis after 1 year therapy.Once HBeAg seroconversion appears,HBcAg and α-SMA in liver decreased.

About this research paper

What this paper is about

Objective:To investigate hepatic pathohistological changes(including pathology,HBV markers in liver tissue) in patients with chronic hepatitis B treated with lamivudine.Methods:35 patients of chronic hepatitis B were randomly selected and administered with 100mg lamivudine orally daily for 1 year.The needle biopsy of liver were performed before and after treatment.The routine HE stained liver tissue sections were evaluated and Knodell pathological score were done.HBsAg,HBcAg,α-SMA in liver tissue were examined by immunohistochemisty method.Results:After 1 year histological assessment revealed that activity index of hepatic histology in 41.18% patients had a significant decrease,while necrosis in portal area,portal vein phlebitis and fibrosis were oboviously alleviated.The liver immunohistochemistry examination showed that HBcAg and α-SMA in liver decreased significantly in the patients with HBeAg seroconversion,but HBsAg had no obvious alteration.Conclusion:These results suggest that lamivudine(100mg/d) alleviate the inflammation degree,slow down the development of liver fibrosis after 1 year therapy.Once HBeAg seroconversion appears,HBcAg and α-SMA in liver decreased.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To investigate hepatic pathohistological changes(including pathology,HBV markers in liver tissue) in patients with chronic hepatitis B treated with lamivudine.Methods:35 patients of chronic hepatitis B were randomly selected and administered with 100mg lamivudine orally daily for 1 year.The needle biopsy of liver were performed before and after treatment.The routine HE stained liver tissue sections were evaluated and Knodell pathological score were done.HBsAg,HBcAg,α-SMA in liver tissue were examined by immunohistochemisty method.Results:After 1 year histological assessment revealed that activity index of hepatic histology in 41.18% patients had a significant decrease,while necrosis in portal area,portal vein phlebitis and fibrosis were oboviously alleviated.The liver immunohistochemistry examination showed that HBcAg and α-SMA in liver decreased significantly in the patients with HBeAg seroconversion,but HBsAg had no obvious alteration.Conclusion:These results suggest that lamivudine(100mg/d) alleviate the inflammation degree,slow down the development of liver fibrosis after 1 year therapy.Once HBeAg seroconversion appears,HBcAg and α-SMA in liver decreased.

Key concepts: HBcAg, Medicine, Lamivudine, HBsAg, HBeAg, Gastroenterology, Liver biopsy, Fibrosis

Related papers

Back to paper searchBrowse research topicsOriginal source
A study on the pathological efficacy of lamivudine in the treatment of chronic hepatitis B — Research Paper | ScholarLens